BioSpace News Archive

PerkinElmer Inc. today announced that the Company will present at the virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023 at 2:15 p.m. ET.

Cell One Partners Inc. today announced a strategic partnership to accelerate the development and commercialization of cell and gene therapies.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing.

The National Institute for Clinical Excellence, a UK government-funded, non-departmental public body that aims to establish guidelines for clinical best practice, recognizes QbTest in its MedTech Innovation Briefing, MIB318.

Teva Pharmaceuticals and NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816), announced today the launch of additional strengths for the generic version of Revlimid® 1 (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States.

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum at 7:30 a.m. PT (10:30 a.m. ET) on Wednesday, March 22, 2023.

Biophytis SA announced that it presents the positive results of the phase 2-3 COVA study with Sarconeos in severe COVID-19 at the European Respiratory Society 2023 21st Lung Science Conference taking place in Estoril, Portugal, between the 9th and the 12th of March 2023.

BerGenBio ASA announced the first patient was dosed in a Phase 1b/2a trial evaluating bemcentinib in combination with the current standard of care, immune checkpoint inhibitor pembrolizumab and doublet chemotherapy, for the treatment of 1st line Non-Small Cell Lung Cancer patients harboring STK11 mutations.

Regenative Labs (Regenative), a leading HCT/P manufacturer, is pleased to announce the publication of its new paper, “The Durability and Efficacy of Cryopreserved Human Umbilical Cord Tissue Allograft for the Supplementation of Cartilage Defects Associated with the Sacroiliac Joint: A Case Series,” with Dr. Albert Lai.

KalVista Pharmaceuticals, Inc . today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2023.